Oesophago-Gastric Cancer: Short Report

Reports | Published: 13 Jun 2019

This is part of a series of short reports exploring specific issues in Oesophago-Gastric (OG) cancer. This short report is entitled: Why do patients with a curative treatment plan for oesophago-gastric cancer not go on to receive surgery?”

The main curative treatment for patients with localised OG cancer is to remove the tumour with surgery (usually along with receiving chemotherapy or chemo-radiotherapy). As many OG patients are diagnosed with the condition at an advanced stage, only 30% of patients are considered as appropriate to receive curative surgery. Additionally, only two-thirds of patients with a plan to receive curative surgery go on to have the surgical resection. This report examines the potential reason for this difference between planned and actual treatments.

Initial examinations conclude that differences are likely observed due to the number of specialists involved in identifying potential treatment options for a patient and that changing patient preferences are also a factor. Furthermore, patient fitness and tumour characteristics may also change before treatment commences leading to change of plan. The National Oesophago-Gastric Cancer Audit plans to follow-up this initial investigation with further evaluation to enable specific recommendations in subsequent works.

Click below to download the report.

Don’t miss out. Sign up to be notified when this resource is updated and to receive updates about other related quality improvement resources, events and news from HQIP. Or you can  .


By continuing you agree to receive emails with updates and other information from HQIP and you are confirming you are over the age of 13.

Please read our privacy policy to understand how HQIP uses the information you provide, your use of HQIP’s website and your interaction with the marketing emails to improve the relevance of the communications we send you. You can unsubscribe at any time.

I have read and agree with the contents of the privacy policy.

Oesophago-Gastric Cancer: Short Report